Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
David MG Halpin. (2023) Clinical Management of COPD in the Real World: Can Studies Reveal Errors in Management and Pathways to Improve Patient Care?. Pragmatic and Observational Research 14, pages 51-61.
Read now
Read now
Tobore Onojighofia Tobore. (2022) On stimulus persistence and human behavior: the stimulus persistence unification theory. Communicative & Integrative Biology 15:1, pages 240-252.
Read now
Read now
Lili Jiang, Tetyana Kendzerska, Shawn D. Aaron, Therese A. Stukel, Matthew B. Stanbrook, Wan Tan, Priscila Pequeno & Andrea S. Gershon. (2022) Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: A Real-World Population Study. COPD: Journal of Chronic Obstructive Pulmonary Disease 19:1, pages 315-323.
Read now
Read now
Jean Bourbeau, Mona Bafadhel, Neil C Barnes, Chris Compton, Valentina Di Boscio, David A Lipson, Paul W Jones, Neil Martin, Gudrun Weiss & David M G Halpin. (2021) Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 499-517.
Read now
Read now
Leah B Sansbury, Chanchal Bains, David A Lipson, Afisi S Ismaila & Sarah H Landis. (2021) Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1255-1264.
Read now
Read now
Beatrice Ludovica Ritondo, Ermanno Puxeddu, Luigino Calzetta, Mario Cazzola & Paola Rogliani. (2021) Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert Opinion on Pharmacotherapy 22:5, pages 611-620.
Read now
Read now
Takeo Suzuki, Jolyon Fairburn-Beech, Keiko Sato & Toshihiko Kaise. (2020) Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan. Current Medical Research and Opinion 36:6, pages 1049-1057.
Read now
Read now
Jennifer K Quint, Alessandra Venerus, Caroline O’Leary, Melissa Myland, Ulf Holmgren, Precil Varghese & Claudia Cabrera. (2020) Prescribing Pathways to Triple Therapy: A Retrospective Observational Study of Adults with Chronic Obstructive Pulmonary Disease in the UK. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3261-3271.
Read now
Read now
Antoni Sicras Mainar, Alicia Huerta, Ruth Navarro Artieda, Eduard Monsó, Sarah H Landis & Afisi S Ismaila. (2019) Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2121-2129.
Read now
Read now
Hana Müllerová, Wilhelmine H Meeraus, Dmitry V Galkin, Frank C Albers & Sarah H Landis. (2019) Clinical burden of illness among patients with severe eosinophilic COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 741-755.
Read now
Read now
Giulia Parri, Dario Nieri, Maria Adelaide Roggi, Barbara Vagaggini, Alessandro Celi & Pierluigi Paggiaro. (2018) Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 12:12, pages 997-1005.
Read now
Read now
Articles from other publishers (7)
Sanjay SethiSwetha R PalliLindsay G S BengtsonErin K BuysmanBrendan ClarkAndrew SargentAsif ShaikhGary T Ferguson. (2023) Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. Journal of Managed Care & Specialty Pharmacy 29:7, pages 791-806.
Crossref
Crossref
Chloe I. Bloom, Jukka Montonen, Olaf Jöns, Elizabeth M. Garry & Surya P. Bhatt. (2022) Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases. Pulmonary Therapy 8:1, pages 75-93.
Crossref
Crossref
Mònica Monteagudo, Alexa Nuñez, Iryna Solntseva, Nafeesa Dhalwani, Alison Booth, Miriam Barrecheguren, Dimitra Lambrelli & Marc Miravitlles. (2021) Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain. Archivos de Bronconeumología 57:3, pages 205-213.
Crossref
Crossref
Mònica Monteagudo, Alexa Nuñez, Iryna Solntseva, Nafeesa Dhalwani, Alison Booth, Miriam Barrecheguren, Dimitra Lambrelli & Marc Miravitlles. (2021) Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain. Archivos de Bronconeumología (English Edition) 57:3, pages 205-213.
Crossref
Crossref
Swetha R. PalliMonica FrazerMary DuCharmeAmi R. BuikemaAmy J. AndersonJessica Franchino-Elder. (2020) Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1363-1374.
Crossref
Crossref
Davide L. Vetrano, Alberto Zucchelli, Elisa Bianchini, Claudio Cricelli, Alessio Piraino, Marco Zibellini, Alberto Ricci, Graziano Onder & Francesco Lapi. (2019) Triple inhaled therapy in COPD patients: determinants of prescription in primary care. Respiratory Medicine 154, pages 12-17.
Crossref
Crossref
Eneida M. Harrison & Victor Kim. (2019) Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease. Respiratory Medicine: X 1, pages 100009.
Crossref
Crossref